Skip to main content
news
People walk past the logo of Japanese trading company Mitsui & Co in Tokyo, Japan, Jan. 10, 2018. REUTERS/Toru Hanai

 

U.S. law firm Cleary Gottlieb Steen & Hamilton, Singapore’s Allen & Gledhill and two Ecuadorian firms have advised Japanese trading house Mitsui & Co on its $360 million investment in an Ecuadoran shrimp farming company.

According to Reuters, Industrial Pesquera Santa Priscila (IPSP) is the world's largest shrimp farming company, and the deal is expected to cement Mitsui’s role in the industry and capture rising consumer demand for higher protein food.

After the closing of the deal, IPSP will become an equity method affiliate of the trading house, which typically means Mitsui will hold more than 20 per cent of the company, Reuters added.

The Ecuadorian firms representing Mitsui were Bustamante Fabara, led by partner Jose Rafael Bustamante, and Robalino. IPSP was represented by Ecuadorian firm Apolo Abogados.

The Allen & Gledhill team included consultant Tan Su May and partners Gabriel Lee and Sunit Chhabra.

The Cleary team was led by partner Chantal Kordula, who was supported by tax partner Maureen Linch, regulatory partner Chase Kaniecki, executive compensation partner Alan Levine, IP partner Marcela Robledo, and real estate partner Joseph Lanzkron.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Cleary, A&O Shearman advise on Goodyear's $701 mln Dunlop sale

Cleary Gottlieb has advised tyremaker Goodyear Tire & Rubber Company on the $701 million sale of its Dunlop brand to Japan's Sumitomo Rubber Industries (SRI), which was represented by A&O Shearman.

Mori Hamada, Nagashima Ohno advise on $1.6 bln bid for Fujitsu General

Japanese law firms Mori Hamada & Matsumoto and Nagashima Ohno & Tsunematsu are playing key roles in Paloma Rheem Holdings' 257 billion yen ($1.6 billion) offer to acquire air conditioner manufacturer Fujitsu General.

CAM, Khaitan, Linklaters act on $355 mln Sai Life Sciences IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas has driven the $355 million initial public offering of TPG-backed Indian healthcare R&D firm Sai Life Sciences, with Khaitan & Co and Linklaters advising the bookrunning lead managers. CAM has also acted for selling promoter shareholders Sai Quest Syn.